Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, Switzerland, specializing in the development of innovative protein-based therapeutics known as DARPins (Designed Ankyrin Repeat Proteins). These novel, custom-built proteins are engineered to target multiple pathways or disease markers simultaneously, opening new avenues in drug design for multifaceted diseases. The company’s pipeline features candidates aimed at treating oncology, immuno-oncology, ophthalmology, and infectious diseases, reflecting its focus on high unmet medical needs. Notably, Molecular Partners AG is advancing DARPin-based therapies for acute myeloid leukemia, solid tumors, and other malignancies, including pioneering projects in radio-labeled DARPin therapies. The company collaborates with leading pharmaceutical firms to bolster its research and expand the potential of its platform across various therapeutic areas. Molecular Partners AG plays a significant role in advancing next-generation biologics in the healthcare and biotechnology sectors, striving to transform treatment paradigms for serious diseases through multi-specific and multi-functional drug candidates.